Please ensure Javascript is enabled for purposes of website accessibility

Why Tandem Diabetes Care Is Soaring 18.5% Higher Today

By Todd Campbell - Apr 10, 2018 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A review of its most recent quarter is sparking investor optimism.

What happened

After Tandem Diabetes Care (TNDM -2.87%) posted a 42% year-over-year increase in sales during the first quarter, its shares are 18.5% higher as of 11:15 a.m. EDT today.

So what

Tandem Diabetes, which makes touchscreen insulin pumps for diabetics, today unveiled preliminary first-quarter results showing growing demand for its lineup.

A computer monitor displaying stock price quotes and an ascending stock price chart.


Specifically, management reported that insulin pump shipments jumped 56% from last year to approximately 4,400 pumps and that, as a result, Tandem Diabetes' sales went up to $27 million. 

The growth benefited from increased sales of its t:slim X2 insulin pump. In its fourth-quarter earnings conference call, management cited the successful launch of integration with Dexcom's G5 Mobile continuous glucose monitor and remote PC functionality as the key drivers of demand for the t:slim X2 pump. 

Tandem Diabetes also updated investors on its balance sheet. It finished March 2018 with approximately $81.9 million in cash, cash equivalents, and short-term investments, including about $64.2 million in net proceeds from an equity financing it completed in February and $6.5 million in net proceeds from warrants that were exercised in the first quarter of 2018. 

Now what

The revenue acceleration is good news because the market for devices that help manage diabetes is becoming increasingly competitive due to new product launches, such as Medtronic's (MDT 0.50%) artificial pancreas. Rising revenue is also important to Tandem Diabetes' long-term survival because the company is yet to turn a profit. Last year, its GAAP operating loss was $62.9 million on $107.6 million in revenue.

Tandem Diabetes plans to report official first-quarter results on April 26, and while it's unlikely those numbers will change meaningfully from these preliminary results, it may still be worth tuning in to see if the company offers new insight into its full-year forecast. Currently, it's guiding for full-year sales of between $132 million to $140 million and a negative operating margin of 35% to 40%. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$71.73 (-2.87%) $-2.12
Medtronic plc Stock Quote
Medtronic plc
$103.18 (0.50%) $0.51
DexCom, Inc. Stock Quote
DexCom, Inc.
$328.14 (-1.97%) $-6.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.